Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PKM | P14618 | 1/20 | 0.33 |
| ▸ | OPRD1 | P41143 | 3/20 | 0.33 |
| ▸ | OPRM1 | P35372 | 2/20 | 0.33 |
| ▸ | OPRK1 | P41145 | 2/20 | 0.33 |
| ▸ | HRH4 | Q9H3N8 | 2/20 | 0.32 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.30 |
| ▸ | KDM1A | O60341 | 2/20 | 0.30 |
| ▸ | DPP8 | Q6V1X1 | 1/20 | 0.30 |
| ▸ | FUCA1 | P04066 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13798076 | 0.83 | ADCY6 (0.31) | OPRD1OPRM1OPRK1 | |
| Trifluoroacetic Acid SCHEMBL3558736 | 0.81 | OPRD1 (0.32) | PKMOPRD1OPRM1OPRK1KDM1A | |
| SCHEMBL3132103 | 0.73 | OPRD1 (0.31) | OPRD1OPRM1OPRK1 | |
| Trifluoroacetic Acid SCHEMBL4307037 | 0.71 | PKM (0.36) | PKMHRH4KDM1A | |
| Trifluoroacetic Acid SCHEMBL3137450 | 0.70 | PKM (0.34) | PKMKDM1A | |
| Trifluoroacetic Acid SCHEMBL5253248 | 0.70 | KDM1A (0.37) | PKMKDM1ADPP8 | |
| Trifluoroacetic Acid SCHEMBL3471327 | 0.70 | TSHR (0.38) | PKMHRH4HRH3KDM1AFUCA1 | |
| Trifluoroacetic Acid SCHEMBL4391008 | 0.70 | TSHR (0.38) | PKMHRH4HRH3KDM1AFUCA1 | |
| Trifluoroacetic Acid SCHEMBL2310563 | 0.68 | OPRD1 (0.57) | OPRD1OPRM1OPRK1 | |
| Trifluoroacetic Acid SCHEMBL4067307 | 0.67 | PKM (0.36) | PKMHRH4HRH3KDM1ADPP8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1861401-B1 | 7-AMINO ALKYLIDENYL-HETEROCYCLIC QUINOLONES AND NAPHTHYRIDONES | JANSSEN PHARMACEUTICA NV (BE) | 2015-11-18 | — | — | EP | disclosed |
| US-7732612-B2 | 7-amino alkylidenyl-heterocyclic quinolones and naphthyridones | JANSSEN PHARMACEUTICA, N.V. (BE) | 2010-06-08 | — | — | US | disclosed |
| WO-2010056633-A2 | 7-AMINO ALKYLIDENYL-HETEROCYCLIC QUINOLONES AND NAPHTHYRIDONES | JANSSEN PHARMACEUTICA NV (BE) | 2010-05-20 | — | — | WO | disclosed |
| US-20090156577-A1 | 7-AMINO ALKYLIDENYL-HETEROCYCLIC QUINOLONES AND NAPHTHYRIDONES | JANSSEN PHARMACEUTICA NV (BE) | 2009-06-18 | — | — | US | disclosed |
| EP-1675852-B1 | 7-AMINO ALKYLIDENYL-HETEROCYCLIC QUINOLONES AND NAPHTHYRIDONES | JANSSEN PHARMACEUTICA NV (BE) | 2009-02-18 | — | — | EP | disclosed |
| EP-1861401-A1 | 7-AMINO ALKYLIDENYL-HETEROCYCLIC QUINOLONES AND NAPHTHYRIDONES | JANSSEN PHARMACEUTICA N.V. (BE) | 2007-12-05 | — | — | EP | disclosed |
| US-7179805-B2 | 7-amino alkylidenyl-heterocyclic quinolones and naphthyridones | JANSSEN PHARMACEUTICA N.V. (BE) | 2007-02-20 | — | — | US | disclosed |
| WO-2006101603-A1 | 7-AMINO ALKYLIDENYL-HETEROCYCLIC QUINOLONES AND NAPHTHYRIDONES | JANSSEN PHARMACEUTICA, N.V. (BE) | 2006-09-28 | — | — | WO | disclosed |
| EP-1675852-A1 | 7-AMINO ALKYLIDENYL-HETEROCYCLIC QUINOLONES AND NAPHTHYRIDONES | Janssen Pharmaceutica N.V. (BE) | 2006-07-05 | — | — | EP | disclosed |
| US-20060052359-A1 | 7-Amino alkylidenyl-heterocyclic quinolones and naphthyridones | JANSSEN PHARMACEUTICA, N.V. (BE) | 2006-03-09 | — | — | US | disclosed |
| US-20050101588-A1 | 7-Amino alkylidenyl-heterocyclic quinolones and naphthyridones | GRANT EUGENE B III (US) | 2005-05-12 | — | — | US | disclosed |
| WO-2005033108-A1 | 7-AMINO ALKYLIDENYL-HETEROCYCLIC QUINOLONES AND NAPHTHYRIDONES | JANSSEN PHARMACEUTICA, N.V. (BE) | 2005-04-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060052359-A1 | 7-Amino alkylidenyl-heterocyclic quinolones and naphthyridones | NQO2, NQO1, REN | PKM 2160/4885OPRD1 618/4885OPRM1 351/4885 |
| US-20050101588-A1 | 7-Amino alkylidenyl-heterocyclic quinolones and naphthyridones | NQO2, NQO1, REN | PKM 2160/4885OPRD1 618/4885OPRM1 351/4885 |
| US-20090156577-A1 | 7-AMINO ALKYLIDENYL-HETEROCYCLIC QUINOLONES AND NAPHTHYRIDONES | NQO2, QRFPR, NQO1 | PKM 2037/4885OPRD1 722/4885OPRM1 439/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.